CTLA4 and neoplasm: Results from our present work revealed that the predictive roles of LOXs expression in tumor immunotherapy were also confirmed in two immunotherapy cohorts including IMvigor 210 (anti-PD-L1 therapy) and Van Allen 2015 (anti-CTLA4 therapy).